TsaiJH, TsaiTF. A review of dupilumab-induced adverse events to dermatologists and the potential pathogenesis in the treatment of atopic dermatitis. Dermatitis. 2024; 35(1):24–42; doi: 10.1089/derm.2022.0096
2.
ShelleyWB, ShelleyED. Nonpigmenting fixed drug eruption as a distinctive reaction pattern: Examples caused by sensitivity to pseudoephedrine hydrochloride and tetrahydrozoline. J Am Acad Dermatol. 1987; 17(3):403–407; doi: 10.1016/s0190-9622(87)70220-5
3.
AlpayA, ErmisB, UgurbasSC, et al.The local vasoconstriction of infant’s skin following instillation of mydriatic eye drops. Eur J Clin Pharmacol. 2010; 66(11):1161–1164; doi: 10.1007/s00228-010-0890-6
4.
SoparkarCN, WilhelmusKR, KochDD, et al.Acute and chronic conjunctivitis due to over-the-counter ophthalmic decongestants. Arch Ophthalmol. 1997; 115(1):34–38; doi: 10.1001/archopht.1997.01100150036004
5.
NahumY, MimouniM, LivnyE, et al.Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: Clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment. Br J Ophthalmol. 2020; 104(6):776–779; doi: 10.1136/bjophthalmol-2019-315010
